
## Brett Garner

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4939098/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Small angle X-ray scattering analysis of ligand-bound forms of tetrameric apolipoprotein-D. Bioscience Reports, 2021, 41, .	2.4	2
2	Generation of <i>APOE</i> knock-down SK-N-SH human neuroblastoma cells using CRISPR/Cas9: a novel cellular model relevant to Alzheimer's disease research. Bioscience Reports, 2021, 41, .	2.4	4
3	Chronic cannabidiol (CBD) treatment did not exhibit beneficial effects in 4-month-old male TAU58/2 transgenic mice. Pharmacology Biochemistry and Behavior, 2020, 196, 172970.	2.9	13
4	Chronic Treatment with 50 mg/kg Cannabidiol Improves Cognition and Moderately Reduces Aβ40 Levels in 12-Month-Old Male AβPPswe/PS11"E9 Transgenic Mice. Journal of Alzheimer's Disease, 2020, 74, 937-950.	2.6	34
5	Sphingosine Kinase 2 Potentiates Amyloid Deposition but Protects against Hippocampal Volume Loss and Demyelination in a Mouse Model of Alzheimer's Disease. Journal of Neuroscience, 2019, 39, 9645-9659.	3.6	22
6	Understanding the Role of ApoE Fragments in Alzheimer's Disease. Neurochemical Research, 2019, 44, 1297-1305.	3.3	51
7	Effect of Fluvoxamine on Amyloid-β Peptide Generation and Memory. Journal of Alzheimer's Disease, 2018, 62, 1777-1787.	2.6	12
8	Wnt is here! Could Wnt signalling be promoted to protect against Alzheimer disease?. Journal of Neurochemistry, 2018, 144, 356-359.	3.9	6
9	The serine protease HtrA1 contributes to the formation of an extracellular 25-kDa apolipoprotein E fragment that stimulates neuritogenesis. Journal of Biological Chemistry, 2018, 293, 4071-4084.	3.4	19
10	Identification of a novel tetrameric structure for human apolipoprotein-D. Journal of Structural Biology, 2018, 203, 205-218.	2.8	12
11	The therapeutic potential of the phytocannabinoid cannabidiol for Alzheimer's disease. Behavioural Pharmacology, 2017, 28, 142-160.	1.7	37
12	Evidence for altered cholesterol metabolism in <scp>H</scp> untington's disease <i>post mortem</i> brain tissue. Neuropathology and Applied Neurobiology, 2016, 42, 535-546.	3.2	58
13	Therapeutic Effects of Anthocyanins and Environmental Enrichment in R6/1 Huntington's Disease Mice. Journal of Huntington's Disease, 2016, 5, 285-296.	1.9	22
14	<i>Abca7</i> deletion does not affect adult neurogenesis in the mouse. Bioscience Reports, 2016, 36, .	2.4	3
15	Beneficial effects of increased lysozyme levels in Alzheimer's disease modelled in Drosophila melanogaster. FEBS Journal, 2016, 283, 3508-3522.	4.7	15
16	Loss of ceramide synthase 2 activity, necessary for myelin biosynthesis, precedes tau pathology in the cortical pathogenesis of Alzheimer's disease. Neurobiology of Aging, 2016, 43, 89-100.	3.1	68
17	Cerebral Apolipoprotein-D Is Hypoglycosylated Compared to Peripheral Tissues and Is Variably Expressed in Mouse and Human Brain Regions. PLoS ONE, 2016, 11, e0148238.	2.5	17
18	Cell Type-Specific Modulation of Cobalamin Uptake by Bovine Serum. PLoS ONE, 2016, 11, e0167044.	2.5	6

#	Article	IF	CITATIONS
19	Understanding the function of ABCA7 in Alzheimer's disease. Biochemical Society Transactions, 2015, 43, 920-923.	3.4	38
20	Fatty Acid Composition of the Anterior Cingulate Cortex Indicates a High Susceptibility to Lipid Peroxidation in Parkinson's Disease. Journal of Parkinson's Disease, 2015, 5, 175-185.	2.8	16
21	Brain Cholesterol Synthesis and Metabolism is Progressively Disturbed in the R6/1 Mouse Model of Huntington's Disease: A Targeted GC-MS/MS Sterol Analysis. Journal of Huntington's Disease, 2015, 4, 305-318.	1.9	19
22	Lysosomal-associated membrane protein 2 isoforms are differentially affected in early Parkinson's disease. Movement Disorders, 2015, 30, 1639-1647.	3.9	123
23	Apolipoprotein D modulates amyloid pathology in APP/PS1 Alzheimer's disease mice. Neurobiology of Aging, 2015, 36, 1820-1833.	3.1	41
24	Perturbation of neuronal cobalamin transport by lysosomal enzyme inhibition. Bioscience Reports, 2014, 34, .	2.4	5
25	Chronic cannabidiol treatment improves social and object recognition in double transgenic APPswe/PS1â^†E9 mice. Psychopharmacology, 2014, 231, 3009-3017.	3.1	115
26	Long-Term Cannabidiol Treatment Prevents the Development of Social Recognition Memory Deficits in Alzheimer's Disease Transgenic Mice. Journal of Alzheimer's Disease, 2014, 42, 1383-1396.	2.6	130
27	Altered ceramide acyl chain length and ceramide synthase gene expression in Parkinson's disease. Movement Disorders, 2014, 29, 518-526.	3.9	112
28	Novel behavioural characteristics of female APPSwe/PS1ΔE9 double transgenic mice. Behavioural Brain Research, 2014, 260, 111-118.	2.2	49
29	Impaired Lysosomal Cobalamin Transport in Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 43, 1017-1030.	2.6	11
30	Analysis of subcellular [57Co] cobalamin distribution in SH-SY5Y neurons and brain tissue. Journal of Neuroscience Methods, 2013, 217, 67-74.	2.5	11
31	An Improved Highâ€Throughput Lipid Extraction Method for the Analysis of Human Brain Lipids. Lipids, 2013, 48, 307-318.	1.7	76
32	Novel behavioural characteristics of the APPSwe/PS1ΔE9 transgenic mouse model of Alzheimer's disease. Behavioural Brain Research, 2013, 245, 120-127.	2.2	53
33	Deletion of <i>Abca7</i> Increases Cerebral Amyloid-β Accumulation in the J20 Mouse Model of Alzheimer's Disease. Journal of Neuroscience, 2013, 33, 4387-4394.	3.6	165
34	Increased Apolipoprotein D Dimer Formation in Alzheimer's Disease Hippocampus is Associated with Lipid Conjugated Diene Levels. Journal of Alzheimer's Disease, 2013, 35, 475-486.	2.6	22
35	Selective reduction of hydroperoxyeicosatetraenoic acids to their hydroxy derivatives by apolipoprotein D: implications for lipid antioxidant activity and Alzheimer's disease. Biochemical Journal, 2012, 442, 713-721.	3.7	62
36	Is Seladin-1 Really a Selective Alzheimer's Disease Indicator?. Journal of Alzheimer's Disease, 2012, 30, 35-39.	2.6	22

#	Article	IF	CITATIONS
37	Dissociation of ERK signalling inhibition from the anti-amyloidogenic action of synthetic ceramide analogues. Clinical Science, 2012, 122, 409-420.	4.3	6
38	Srp20 regulates TrkB preâ€mRNA splicing to generate TrkBâ€6hc transcripts with implications for Alzheimer's disease. Journal of Neurochemistry, 2012, 123, 159-171.	3.9	28
39	Cognitive phenotyping of amyloid precursor protein transgenic J20 mice. Behavioural Brain Research, 2012, 228, 392-397.	2.2	40
40	Evidence that truncated TrkB isoform, TrkB-Shc can regulate phosphorylated TrkB protein levels. Biochemical and Biophysical Research Communications, 2012, 420, 331-335.	2.1	19
41	Molecular Dynamics Analysis of Apolipoprotein-D - Lipid Hydroperoxide Interactions: Mechanism for Selective Oxidation of Met-93. PLoS ONE, 2012, 7, e34057.	2.5	24
42	Role of Abca7 in Mouse Behaviours Relevant to Neurodegenerative Diseases. PLoS ONE, 2012, 7, e45959.	2.5	39
43	Sensitivity to Lysosome-Dependent Cell Death Is Directly Regulated by Lysosomal Cholesterol Content. PLoS ONE, 2012, 7, e50262.	2.5	66
44	Attenuation of the Lysosomal Death Pathway by Lysosomal Cholesterol Accumulation. American Journal of Pathology, 2011, 178, 629-639.	3.8	92
45	Isoform-specific proteolysis of apolipoprotein-E in the brain. Neurobiology of Aging, 2011, 32, 257-271.	3.1	49
46	Wild Type and Tangier Disease ABCA1 Mutants Modulate Cellular Amyloid-β Production Independent of Cholesterol Efflux Activity. Journal of Alzheimer's Disease, 2011, 27, 441-452.	2.6	11
47	Mass and relative elution time profiling: two-dimensional analysis of sphingolipids in Alzheimer's disease brains. Biochemical Journal, 2011, 438, 165-175.	3.7	45
48	Age-related lysosomal dysfunction: an unrecognized roadblock for cobalamin trafficking?. Cellular and Molecular Life Sciences, 2011, 68, 3963-3969.	5.4	12
49	Lipid Pathway Alterations in Parkinson's Disease Primary Visual Cortex. PLoS ONE, 2011, 6, e17299.	2.5	142
50	The Kynurenine Pathway and Inflammation in Amyotrophic Lateral Sclerosis. Neurotoxicity Research, 2010, 18, 132-142.	2.7	116
51	Vascular Pharmacotherapy and Dementia. Current Vascular Pharmacology, 2010, 8, 44-50.	1.7	3
52	Increased ATP-Binding Cassette Transporter A1 Expression in Alzheimer's Disease Hippocampal Neurons. Journal of Alzheimer's Disease, 2010, 21, 193-205.	2.6	39
53	Modulation of amyloid precursor protein processing by synthetic ceramide analogues. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2010, 1801, 887-895.	2.4	15
54	Apolipoproteins in the brain: implications for neurological and psychiatric disorders. Clinical Lipidology, 2010, 5, 555-573.	0.4	157

#	Article	IF	CITATIONS
55	Apolipoproteinâ€D expression is increased during development and maturation of the human prefrontal cortex. Journal of Neurochemistry, 2009, 109, 1053-1066.	3.9	36
56	Impact of 27-Hydroxycholesterol on Amyloid-β Peptide Production and ATP-Binding Cassette Transporter Expression in Primary Human Neurons. Journal of Alzheimer's Disease, 2009, 16, 121-131.	2.6	55
57	Modulation of brain metabolism by very low concentrations of the commonly used drug delivery vehicle dimethyl sulfoxide (DMSO). Journal of Neuroscience Research, 2008, 86, 208-214.	2.9	47
58	Role of ATPâ€binding cassette transporters in brain lipid transport and neurological disease. Journal of Neurochemistry, 2008, 104, 1145-1166.	3.9	201
59	ATPâ€binding cassette transporter A7 regulates processing of amyloid precursor protein <i>in vitro</i> . Journal of Neurochemistry, 2008, 106, 793-804.	3.9	124
60	Reduction of plasma glycosphingolipid levels has no impact on atherosclerosis in apolipoprotein E-null mice. Journal of Lipid Research, 2008, 49, 1677-1681.	4.2	26
61	Myriocin slows the progression of established atherosclerotic lesions in apolipoprotein E gene knockout mice. Journal of Lipid Research, 2008, 49, 324-331.	4.2	51
62	Regulation of α-synuclein expression by liver X receptor ligands in vitro. NeuroReport, 2008, 19, 1685-1689.	1.2	28
63	Role of ABCG1 and ABCA1 in Regulation of Neuronal Cholesterol Efflux to Apolipoprotein E Discs and Suppression of Amyloid-1 <sup>2</sup> Peptide Generation. Journal of Biological Chemistry, 2007, 282, 2851-2861.	3.4	168
64	Apoptosis induces neuronal apolipoprotein-E synthesis and localization in apoptotic bodies. Neuroscience Letters, 2007, 416, 206-210.	2.1	38
65	Characterization of the Kynurenine Pathway in Human Neurons. Journal of Neuroscience, 2007, 27, 12884-12892.	3.6	265
66	Alanine metabolism, transport, and cycling in the brain. Journal of Neurochemistry, 2007, 102, 1758-1770.	3.9	48
67	Inhibition of atherosclerosis by the serine palmitoyl transferase inhibitor myriocin is associated with reduced plasma glycosphingolipid concentration. Biochemical Pharmacology, 2007, 73, 1340-1346.	4.4	66
68	HPLC analysis of discrete haptoglobin isoform N-linked oligosaccharides following 2D-PAGE isolation. Biochemical and Biophysical Research Communications, 2006, 343, 496-503.	2.1	33
69	Quantitation of ATP-binding cassette subfamily-A transporter gene expression in primary human brain cells. NeuroReport, 2006, 17, 891-896.	1.2	123
70	Fine Tuning Therapeutic Targeting of the Sphingolipid Biosynthetic Pathway to Treat Atherosclerosis. Current Vascular Pharmacology, 2006, 4, 151-154.	1.7	8
71	Dolichol is the major lipid component of human substantia nigra neuromelanin. Journal of Neurochemistry, 2005, 92, 990-995.	3.9	61
72	Glycosphingolipid Accumulation Inhibits Cholesterol Efflux via the ABCA1/Apolipoprotein A-I Pathway. Journal of Biological Chemistry, 2005, 280, 24515-24523.	3.4	71

#	Article	IF	CITATIONS
73	Heterogeneous expression of apolipoprotein-E by human macrophages. Immunology, 2004, 113, 338-347.	4.4	13
74	Induction of fibroblast apolipoprotein E expression during apoptosis, starvation-induced growth arrest and mitosis. Biochemical Journal, 2004, 378, 753-761.	3.7	38
75	Modulation of THP-1 Macrophage and Cholesterol-Loaded Foam Cell Apolipoprotein E Levels by Glycosphingolipids. Biochemical and Biophysical Research Communications, 2002, 290, 1361-1367.	2.1	30
76	Increased glycosphingolipid levels in serum and aortae of apolipoprotein E gene knockout mice. Journal of Lipid Research, 2002, 43, 205-14.	4.2	50
77	Structural Elucidation of the N- andO-Glycans of Human Apolipoprotein(a). Journal of Biological Chemistry, 2001, 276, 22200-22208.	3.4	79
78	Characterisation of the major autoxidation products of 3-hydroxykynurenine under physiological conditions. Free Radical Research, 2000, 32, 11-23.	3.3	75
79	Formation of Hydroxyl Radicals in the Human Lens is Related to the Severity of Nuclear Cataract. Experimental Eye Research, 2000, 70, 81-88.	2.6	59
80	Distribution of Ferritin and Redox-active Transition Metals in Normal and Cataractous Human Lenses. Experimental Eye Research, 2000, 71, 599-607.	2.6	37
81	Identification of Glutathionyl-3-hydroxykynurenine Glucoside as a Novel Fluorophore Associated with Aging of the Human Lens. Journal of Biological Chemistry, 1999, 274, 20847-20854.	3.4	68
82	Human Lens Coloration and Aging. Journal of Biological Chemistry, 1999, 274, 32547-32550.	3.4	111
83	Endogenous ferritin protects cells with iron-laden lysosomes against oxidative stress. Free Radical Research, 1998, 29, 103-114.	3.3	70
84	Oxidation of High Density Lipoproteins. Journal of Biological Chemistry, 1998, 273, 6080-6087.	3.4	168
85	Oxidation of High Density Lipoproteins. Journal of Biological Chemistry, 1998, 273, 6088-6095.	3.4	296
86	On the Cytoprotective Role of Ferritin in Macrophages and its Ability to Enhance Lysosomal Stability. Free Radical Research, 1997, 27, 487-500.	3.3	44
87	Regulation of serum-induced lipid accumulation in human monocyte-derived macrophages by interferon- Î <sup>3</sup> . Correlations with apolipoprotein E production, lipoprotein lipase activity and LDL receptor-related protein expression. Atherosclerosis, 1997, 128, 47-58.	0.8	43
88	Direct Copper Reduction by Macrophages. Journal of Biological Chemistry, 1997, 272, 6927-6935.	3.4	45